Featured news from NHIVNA
HIV-related news from NAM
Dolutegravir monotherapy fails to maintain HIV viral suppression, but dolutegravir + lamivudine looks good
Liz Highleyman, 2017-03-09 10:00:00
Dolutegravir used alone without other antiretrovirals
was unable to keep viral load suppressed in some people who switched from a
standard three-drug combination regimen, according to research presented at the
2017 Conference on Retroviruses and Opportunistic Infections (CROI) last month
in Seattle. But evidence continues to show that dolutegravir plus a single
other drug can work well as maintenance therapy.
In an effort to make antiretroviral therapy (ART) more
convenient, better tolerated and less expensive, researchers have tried to
simplify HIV treatment by reducing the number of drugs in maintenance regimens
for people who have achieved undetectable viral load on multi-drug combinations.
Dolutegravir (Tivicay) is a potent and
well tolerated integrase inhibitor with a high genetic barrier to resistance,
making it a good candidate for simplified therapy.